CareCost Prior authorization
Required
Check what the payer requires before you schedule Orencia.
29 payers, 535 rules, and methotrexate or a conventional DMARD first at 28 of them.
29 payer policy sets hold an abatacept policy · source-linked · reviewed August 2026
Aetna + rheumatoid arthritis is shown as a live example until you choose a payer.
This payer requires an approval on file before Orencia is purchased or infused for this member.
Precertification of intravenous abatacept (Orencia IV) is required of all Aetna participating providers and members in applicable plan designs.
moderately to severely active RA in adults
For adult members for treatment of moderately to severely active RA when both
What opens in CareCost
Aetna · Orencia · Rheumatoid arthritis
For every requirement: the exact payer criteria, the source citation, a check-off, and a save to the patient’s chart.
In CareCost: check off each requirement · save to the patient · print for the chart
Aetna · Orencia · Rheumatoid arthritis
You have already checked the policy, indication and covered dose. Open the remaining requirements and work them as a patient checklist.
CareCost tracks Orencia coverage requirements across 29 payer policy sets.
Aetna · Anthem / Elevance · UnitedHealthcare · Cigna · CareFirst BCBS · BCBS plans + more
Coverage clearance is only the first step.
CareCost carries the same patient through the entire workflow.
Finish this patient’s estimate →26 of 29 commercial payers with an abatacept policy require prior authorization. Almost every payer in this corpus requires methotrexate or a conventional synthetic DMARD first, several add a second preferred biologic, and reauthorization timing, quantity limits and site-of-care rules vary by plan.
The 535 rules break out as 325 clinical prerequisites, 105 covered-indication rules, 29 dosing rules, 27 prior-authorization rules, 15 site-of-care rules, 15 quantity limits, 12 contraindication exclusions, 3 reauthorization rules, 2 step-therapy-elsewhere rules, and one each of billing-coding and combination rules — 325 clinical prerequisites is the deepest step-therapy corpus CareCost has read after infliximab.
26 require PA · 15 cap quantity or duration · 15 address site of care
26 of the 29 payers CareCost has read require an approval on file before abatacept is covered. Aetna’s precertification rule reads: “Precertification of intravenous abatacept (Orencia IV) is required of all Aetna participating providers and members in applicable plan designs.” The other 3 apply the same clinical review without a formal prior-authorization label; the documentation burden is the same either way.
Almost every payer in this corpus wants a cheaper drug tried and failed before Orencia. Anthem: “Individual has had an inadequate response to methotrexate titrated to maximally tolerated dose”, and separately “a trial and inadequate response or intolerance to two (2) preferred agents”. BCBS Florida and HCSC both require “maximally tolerated methotrexate (e.g., titrated to 25 mg weekly)…”. BCBS Arkansas: “active disease with inadequate response (trial of greater than or equal to 3 months) to at least one conventional synthetic DMARDs”. Aetna phrases the same idea as a class requirement: “member has a contraindication, intolerance or ineffective response to all of the following available equivalent alternative targeted immune modulators (one-month trial each): Avtozma, Simponi Aria”. The one payer in this corpus without that quote is BCBS Massachusetts.
A recurring question in this corpus is whether the patient could inject the drug without a clinician present. BCBS Kansas asks the physician to attest the patient “is not competent or is physically unable to administer the Orencia product FDA labeled for self-administration”, with an exception when the “patient has experienced severe hypersensitivity reactions…” recently. BCBS Florida: “If intravenous abatacept (Orencia) is administered in a hospital-affiliated outpatient setting, additional requirements may apply”. CareFirst allows “the first two infusions” in the hospital outpatient setting before steering elsewhere. Blue Shield of California names its “preferred site of service, including the home, a physician’s office, or an independent infusion center not associated with a hospital”. Highmark (HMHS) will pay when Orencia is “administered in a physician’s office not affiliated with a hospital, specialized infusion centers not affiliated with a hospital or in the home”.
Fifteen rules cap the amount, and several state it as a pharmacy count rather than a milligram ceiling. HCSC: “Orencia Abatacept For IV Soln 250 MG 250 MG 4 Vials 28 Days”. Wellmark: “4 vials or syringes/auto-injectors per 28 days”. BCBS Minnesota and Capital BlueCross both cap the rheumatology indications at “Loading: 100 billable units at weeks 0, 2, & 4… Maintenance: 100 billable units per 4 weeks”, then separately allow “Prophylaxis for aGVHD… 400 billable units per 29 days”. BCBS Tennessee writes the same ceilings by weight band: “≥101kg Initial: 1000mg on weeks 0, 2, and 4 Maintenance: 1000mg every 4 weeks”. For acute GvHD prophylaxis, the quantity limit is a dose count rather than a milligram figure: UnitedHealthcare, “Authorization is for no more than 4 doses”; Centene, “Approval duration: 3 months (4 doses total)”, matching the label’s own fixed course at day -1 and days 5, 14 and 28.
Only 3 rules in this corpus address renewal directly, and all of them tie continuation to evidence the drug is working rather than a fixed calendar date. BCBS Michigan: “Clinical documentation must be provided to confirm that current criteria are met and that the medication is providing clinical benefit”. Centene: “Currently receiving medication via Centene benefit or member has previously met initial approval criteria”, and for rheumatoid arthritis specifically, “Member is responding positively to therapy as evidenced by one of the following”.
Not every payer covers Orencia’s whole label. Rheumatoid arthritis and polyarticular JIA each carry a covered-indication rule at 28 of the 29 payers; psoriatic arthritis at 27; acute graft-versus-host disease prophylaxis, the narrowest, at 21. A payer that covers one of those does not automatically cover the rest — check the diagnosis on this patient’s claim against the payer’s own list before assuming the whole policy applies.
No abatacept biosimilar exists. When a payer’s policy asks for another product first, it is naming Orencia’s reference-drug family or an infliximab biosimilar, not a copy of Orencia itself.
| Product | Code | Maker | On this page |
|---|---|---|---|
| Orencia | J0129 | Bristol Myers Squibb | This page |
| Remicade | J1745 | Janssen | Named as a preferred agent |
| Actemra (IV) | J3262 | Genentech | Named as a preferred agent |
| Simponi Aria | J1602 | Janssen | Named as a preferred agent |
Several payers in this corpus name Remicade or Simponi Aria directly. CareFirst requires “documented inadequate response or intolerable adverse event with Entyvio, Ilumya, Remicade, and Simponi Aria where the product’s indications overlap”. Highmark (HMHS) requires “…at least one (1) preferred IV biologic (infliximab [Remicade®], infliximab-dyyb [Inflectra®], or golimumab [Simponi Aria®]) was ineffective or not tolerated”. Independence Blue Cross wants “documented failure, contraindication, or intolerance to infliximab (Remicade) or golimumab (Simponi Aria)” for rheumatoid arthritis, and adds ustekinumab (Stelara) to that list for psoriatic arthritis.
Wellmark asks for “…inadequate response or intolerable adverse event with each of the following: 1) Avsola 2) Inflectra 3) Simponi Aria”, two infliximab biosimilars plus Simponi Aria rather than the Remicade originator itself. Centene’s psoriatic-arthritis rule reads the same way: “Failure of one of the following, used for ≥ 3 consecutive months: Avsola, Inflectra, Renflexis, or Simponi Aria”. Excellus requires “…failure or serious side effects with of Inflectra/Avsola or Simponi Aria” for rheumatoid arthritis and adds Selarsdi/Yesintek and Tremfya to its psoriatic-arthritis list.
Each billable code on Orencia’s manifest carries its own dxKey in the Clearance corpus, so the payer count that applies changes with what’s on the claim.
| Indication | ICD-10 | dxKey | Payers with a covered-indication rule |
|---|---|---|---|
| Moderately to severely active rheumatoid arthritis | M06.9 | rheumatoid_arthritis | 28 of 29 |
| Active psoriatic arthritis | L40.50 | psoriatic_arthritis | 27 of 29 |
| Polyarticular juvenile idiopathic arthritis | M08.00 | juvenile_idiopathic_arthritis | 28 of 29 |
| Prophylaxis of acute graft-versus-host disease | D89.810 | acute_gvhd_prophylaxis | 21 of 29 |
CareCost’s diagnosis picker above offers all four. Acute GvHD prophylaxis is the narrowest indication in this corpus and the only one authorized as a fixed four-dose course rather than an open-ended maintenance schedule.
Part B pays for Orencia at the ASP-based rate for J0129, the same buy-and-bill mechanism as any other infused specialty drug; nothing in this corpus documents a national coverage determination or a registry requirement specific to abatacept. A Medicare Advantage plan administers that same benefit but can layer its own prior-authorization and site-of-care rules on top, including the ones quoted above. Check the plan’s own policy rather than assuming these rules carry over.
Orencia is billed with 96365 (therapeutic infusion, initial hour) alone, non-facility PFS $67.14; 96366 (each additional hour) does not apply at either the 30-minute rheumatology infusion or the 60-minute acute GvHD prophylaxis infusion, and 96413 (chemotherapy administration) is the wrong code family for a T-cell costimulation modulator. The Medicare unit-of-service limit (MUE) for J0129 is 100 units, matching the labeled 1,000 mg maximum dose.
Payer citation language above is drawn from CareCost’s own abatacept policy corpus (29 payers, 535 rules). Check the specific payer’s language →
It depends on the payer and plan. 26 of the 29 abatacept policies CareCost has read require prior authorization before Orencia is covered. The other 3 apply the same clinical review without a formal prior-authorization label; the documentation burden is the same either way. Check this patient’s payer →
Yes, at 28 of the 29 payers in this corpus. Anthem: “Individual has had an inadequate response to methotrexate titrated to maximally tolerated dose”. BCBS Arkansas: “active disease with inadequate response (trial of greater than or equal to 3 months) to at least one conventional synthetic DMARDs”. The one payer in this corpus without that quote is BCBS Massachusetts. Check this patient’s payer →
It depends on the payer. 15 rules in this corpus turn on whether the patient can self-administer instead. BCBS Kansas: “Physician attests that the patient or caregiver is not competent or is physically unable to administer the Orencia product FDA labeled for self-administration”. CareFirst allows “the first two infusions” in the hospital outpatient setting before steering elsewhere. Check this patient’s payer →
Yes. HCSC lists it as “Orencia Abatacept For IV Soln 250 MG 250 MG 4 Vials 28 Days”, and Wellmark caps it at “4 vials or syringes/auto-injectors per 28 days”, both matching the labeled 1,000 mg maximum. Check this patient’s payer →
Exactly four. UnitedHealthcare: “Authorization is for no more than 4 doses”. Centene: “Approval duration: 3 months (4 doses total)”. The label itself is a fixed four-infusion course around transplant, at day -1 and days 5, 14 and 28. Check this patient’s payer →
Data current: payer policies Aug 2026 · reviewed dates come from each payer
Payer medical and pharmacy policies · prior-authorization criteria · clinical coverage criteria. ICD-10 codes verified against the NLM Clinical Table Search Service. Medicare coverage and fee-schedule amounts from the CMS Medicare Coverage Database and the Medicare Physician Fee Schedule. Every CareCost requirement links back to its source policy.